Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(4.54)
# 250
Out of 5,182 analysts
132
Total ratings
52.46%
Success rate
25.74%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LENZ LENZ Therapeutics | Maintains: Buy | $56 → $48 | $9.99 | +380.48% | 8 | Apr 21, 2026 | |
| FBLG FibroBiologics | Maintains: Buy | $4 → $8 | $1.56 | +412.82% | 10 | Apr 16, 2026 | |
| KOD Kodiak Sciences | Reiterates: Buy | $38 → $58 | $45.19 | +28.35% | 10 | Mar 27, 2026 | |
| SRZN Surrozen | Reiterates: Buy | $32 → $36 | $33.03 | +8.99% | 4 | Mar 24, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterates: Buy | $36 | $9.80 | +267.35% | 19 | Mar 20, 2026 | |
| ALDX Aldeyra Therapeutics | Downgrades: Neutral | $10 → $2 | $1.70 | +17.65% | 14 | Mar 18, 2026 | |
| ZBIO Zenas BioPharma | Reiterates: Buy | $44 | $20.07 | +119.23% | 7 | Mar 17, 2026 | |
| IMUX Immunic | Maintains: Buy | $8 → $5 | $0.90 | +455.56% | 8 | Mar 2, 2026 | |
| ARDX Ardelyx | Maintains: Buy | $10 → $18 | $6.02 | +199.00% | 2 | Feb 20, 2026 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $6 | $1.42 | +322.54% | 4 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $28.93 | +93.57% | 13 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $26 | $11.73 | +121.65% | 11 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $88 | $63.48 | +38.63% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $6.47 | +85.47% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $5.47 | +46.25% | 4 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 | $9.60 | -6.25% | 8 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $690.06 | -95.94% | 1 | Aug 22, 2023 |
LENZ Therapeutics
Apr 21, 2026
Maintains: Buy
Price Target: $56 → $48
Current: $9.99
Upside: +380.48%
FibroBiologics
Apr 16, 2026
Maintains: Buy
Price Target: $4 → $8
Current: $1.56
Upside: +412.82%
Kodiak Sciences
Mar 27, 2026
Reiterates: Buy
Price Target: $38 → $58
Current: $45.19
Upside: +28.35%
Surrozen
Mar 24, 2026
Reiterates: Buy
Price Target: $32 → $36
Current: $33.03
Upside: +8.99%
4D Molecular Therapeutics
Mar 20, 2026
Reiterates: Buy
Price Target: $36
Current: $9.80
Upside: +267.35%
Aldeyra Therapeutics
Mar 18, 2026
Downgrades: Neutral
Price Target: $10 → $2
Current: $1.70
Upside: +17.65%
Zenas BioPharma
Mar 17, 2026
Reiterates: Buy
Price Target: $44
Current: $20.07
Upside: +119.23%
Immunic
Mar 2, 2026
Maintains: Buy
Price Target: $8 → $5
Current: $0.90
Upside: +455.56%
Ardelyx
Feb 20, 2026
Maintains: Buy
Price Target: $10 → $18
Current: $6.02
Upside: +199.00%
Akebia Therapeutics
Feb 6, 2026
Reiterates: Buy
Price Target: $6
Current: $1.42
Upside: +322.54%
Nov 12, 2025
Maintains: Buy
Price Target: $52 → $56
Current: $28.93
Upside: +93.57%
Oct 31, 2025
Maintains: Buy
Price Target: $20 → $26
Current: $11.73
Upside: +121.65%
Oct 20, 2025
Maintains: Buy
Price Target: $72 → $88
Current: $63.48
Upside: +38.63%
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $6.47
Upside: +85.47%
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $5.47
Upside: +46.25%
May 19, 2025
Reiterates: Neutral
Price Target: $9
Current: $9.60
Upside: -6.25%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $690.06
Upside: -95.94%